X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES BIOCON LTD JUBILANT LIFE SCIENCES/
BIOCON LTD
 
P/E (TTM) x 17.1 92.4 18.5% View Chart
P/BV x 4.5 7.8 57.3% View Chart
Dividend Yield % 0.4 0.1 274.2%  

Financials

 JUBILANT LIFE SCIENCES   BIOCON LTD
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
BIOCON LTD
Mar-18
JUBILANT LIFE SCIENCES/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1871,188 15.7%   
Low Rs65305 21.3%   
Sales per share (Unadj.) Rs364.368.7 530.2%  
Earnings per share (Unadj.) Rs6.87.6 90.7%  
Cash flow per share (Unadj.) Rs24.514.0 175.4%  
Dividends per share (Unadj.) Rs3.001.00 300.0%  
Dividend yield (eoy) %2.40.1 1,778.1%  
Book value per share (Unadj.) Rs164.986.3 191.0%  
Shares outstanding (eoy) m159.28600.00 26.5%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.310.9 3.2%   
Avg P/E ratio x18.498.9 18.6%  
P/CF ratio (eoy) x5.153.4 9.6%  
Price / Book Value ratio x0.88.6 8.8%  
Dividend payout %43.813.2 330.9%   
Avg Mkt Cap Rs m20,061447,900 4.5%   
No. of employees `0006.26.1 100.6%   
Total wages/salary Rs m11,0529,311 118.7%   
Avg. sales/employee Rs Th9,383.06,705.8 139.9%   
Avg. wages/employee Rs Th1,786.91,514.2 118.0%   
Avg. net profit/employee Rs Th176.3736.9 23.9%   
INCOME DATA
Net Sales Rs m58,03441,234 140.7%  
Other income Rs m1912,062 9.2%   
Total revenues Rs m58,22443,296 134.5%   
Gross profit Rs m5,7868,291 69.8%  
Depreciation Rs m2,8123,851 73.0%   
Interest Rs m3,237615 526.4%   
Profit before tax Rs m-725,887 -1.2%   
Minority Interest Rs m-286213 -134.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m6961,569 44.4%   
Profit after tax Rs m1,0904,531 24.1%  
Gross profit margin %10.020.1 49.6%  
Effective tax rate %-965.926.7 -3,624.1%   
Net profit margin %1.911.0 17.1%  
BALANCE SHEET DATA
Current assets Rs m29,28041,486 70.6%   
Current liabilities Rs m38,91221,413 181.7%   
Net working cap to sales %-16.648.7 -34.1%  
Current ratio x0.81.9 38.8%  
Inventory Days Days8464 131.9%  
Debtors Days Days5194 53.8%  
Net fixed assets Rs m55,71250,661 110.0%   
Share capital Rs m1553,000 5.2%   
"Free" reserves Rs m20,96848,808 43.0%   
Net worth Rs m26,26551,808 50.7%   
Long term debt Rs m17,16917,898 95.9%   
Total assets Rs m88,60699,897 88.7%  
Interest coverage x1.010.6 9.2%   
Debt to equity ratio x0.70.3 189.2%  
Sales to assets ratio x0.70.4 158.7%   
Return on assets %4.95.2 94.8%  
Return on equity %4.28.7 47.5%  
Return on capital %11.69.6 120.1%  
Exports to sales %37.80-   
Imports to sales %16.50-   
Exports (fob) Rs m21,933NA-   
Imports (cif) Rs m9,567NA-   
Fx inflow Rs m22,00412,058 182.5%   
Fx outflow Rs m11,7497,348 159.9%   
Net fx Rs m10,2554,710 217.7%   
CASH FLOW
From Operations Rs m8,0266,621 121.2%  
From Investments Rs m-1,744-6,840 25.5%  
From Financial Activity Rs m-4,447-2,397 185.5%  
Net Cashflow Rs m1,834-2,612 -70.2%  

Share Holding

Indian Promoters % 45.6 40.4 112.9%  
Foreign collaborators % 3.5 20.6 17.0%  
Indian inst/Mut Fund % 8.7 8.4 103.6%  
FIIs % 21.2 10.7 198.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 19.9 106.0%  
Shareholders   23,815 109,995 21.7%  
Pledged promoter(s) holding % 15.9 0.0 39,625.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare JUBILANT LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY18); Net Profit Up 1.4% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 1.4% YoY). Sales on the other hand came in at Rs 23 bn (up 37.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

BIOCON LTD Announces Quarterly Results (4QFY18); Net Profit Up 19.8% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 19.8% YoY). Sales on the other hand came in at Rs 12 bn (up 25.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Sep 21, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 5-YR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS